Strategic Collaboration Between SK Bioscience and Novavax: Accelerating Vaccine Research and Global Expansion

Recently, South Korean innovative vaccine and biotechnology company SK Bioscience announced a strategic equity investment in the leading global protein vaccine company Novavax. Through a private placement, SK Bioscience acquired 6.5 million shares of Novavax’s common stock. Behind this strategic investment lies the transformation of the two companies’ collaborative relationship from partners during the peak of the pandemic to a long-term synergistic cooperation in the post-pandemic era, aimed at better addressing changes in the global health environment.

Related article: SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center

Both companies aim to expand their collaborative scope

As a company committed to prevention and treatment, SK Bioscience is not only injecting funds but also demonstrating its dedication to global health. This equity investment makes SK Bioscience a shareholder in Novavax, strengthening the close connection between the two companies. Simultaneously, it symbolizes the transition from being pandemic-era partners to long-term collaborative partners during the post-epidemic period. In this process, both companies will gradually transform from emergency response to long-term development, showcasing their determination to cooperate in confronting global pandemics.

In addition to investment, SK Bioscience and Novavax have also reached an agreement to expand their collaboration. According to this agreement, SK Bioscience will gain exclusive rights to operate the updated version of Novavax’s COVID-19 vaccine in South Korea, as well as non-exclusive supply and commercialization rights in Thailand and Vietnam. This not only expands SK Bioscience’s participation in the vaccine market but also provides strong support for epidemic prevention efforts in both countries.

The collaboration between SK Bioscience and Novavax will also involve the use of Novavax’s innovative adjuvant technology, Matrix-M™, which involves complex lipid nanoparticles that activate the immune system, enhancing the effectiveness of vaccines against pathogens and strengthening the durability and intensity of immune responses. These two companies are dedicated to utilizing Matrix-M technology to enhance SK Bioscience’s vaccine research and manufacturing capabilities, particularly for the development of COVID-19 vaccines.

Realigning Strategies to Face Market Challenges

During the prevalence of the COVID-19 pandemic, Novavax faced challenges in launching their vaccines. However, as the pandemic draws to a close, they hope to rejuvenate through collaboration with SK Bioscience. SK Bioscience acquired 7% of Novavax’s shares for $85 million, totaling 6.5 million shares. The price of $13 per share represents a 59% premium over Novavax’s average price in the previous 90 days. This transaction also relieves Novavax of its $195 million debt to SK Bioscience, reducing its total debt by over $1 billion.

In the second quarter, Novavax closed with revenues of $424 million and earnings per share of $0.58, a significant progress for Novavax, especially given that the new CEO, John Jacobs, warned that Novavax might not be able to survive through 2023.

As Novavax enters the vaccine commercialization stage, the company plans to charge $130 per dose for the vaccine. The company has already submitted an updated vaccine approval application to the FDA and is expected to launch in September. Additionally, they anticipate submitting applications in Europe and Canada in the coming weeks.

Expanding Prospects and Creating Value

This collaboration will aid SK Bioscience in its strategic positioning in the global vaccine market. SK Bioscience not only plans to develop its own vaccines but also to rapidly respond to the vaccine demands of global pharmaceutical companies. This dual-track strategy will enable the company to better navigate market changes, ensure stable vaccine supply, and achieve robust business operations.

On the other hand, SK Bioscience will continue to strengthen its collaboration with international organizations and biopharmaceutical companies to develop new vaccines. Through this “globalization” initiative, the company plans to establish research and manufacturing bases in different countries to meet global vaccine demands. SK Bioscience’s first step is to establish a research and manufacturing base in the United States, known as SK Bioscience USA. This will aid the company in accelerating its entry into the US and European markets, realizing its strategic goal of global expansion. By establishing a base in the United States, SK Bioscience will be more flexible in responding to regional demands and will gain greater influence and competitiveness in the international market.

The equity investment and strategic collaboration between SK Bioscience and Novavax not only demonstrate trust and cooperation at the commercial level but also bring new hope to the global health field. This collaboration will continue to achieve new milestones in epidemic prevention, jointly driving the development of both parties in the healthcare industry.

Author

Sinead Huang